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Problem Definition

American Academy of Sleep Medicine (AASM)
recommends all sleep disorders centers (SDC)
routinely perform urine drug screens (UDS) in
patients undergoing a multiple sleep latency test
(MSLT) or maintenance of wakefulness test (MWT)
to identify substances that can alter results of
testing. Many substances can affect the results of
an MSLT or MST, which influences management of
sleep disorders going forward. Our research has
shown most academic SDC have implemented this;
however, we have not.

Aims For Improvement

Aim:
Introduce UDS
for all patients
undergoing MSLT
or MWT

Eliminate false
positive and
negative results

Optimize
management of
disorder

Based on data we collected from surveying
academic SDC, we predict that once implemented,
the most common positive result will be for
marijuana (THC) followed by benzodiazepines. We
also hypothesize about 15-20% of tests will be
positive based on the our survey and the current
literature.

Goal: To have 100% of patients undergoing an
MSLT or MWT to have a UDS
Intervention

Patients who are scheduled to undergo an MSLT or
MWT will be informed of the UDS as routine
protocol for these procedures at their office visit.
They will be given written notice in the after visit
summary.

Similar to the SDC that do not check UDS, the
logistics of administering the screening has been
the biggest barrier to implementation at our center.

Prior to the start of their sleep study procedure, a
urine specimen will be collected by our lab staff and
run by the hospital lab as a 7 panel test. Regardless
of the outcome of screening, the sleep study will
proceed. If screening returns positive, this will be
factored into the interpretation of the study.
Measurement and Results

The primary goal of this intervention is to establish
a protocol that meets the standard of care
recommended by the AASM. An additional
outcomes will be to evaluate the frequency of
positive drug tests compared to what patients
declare they are taking.
Due to COVID-19 the implementation of UDS at
our SDC has been postponed until the lab returns
to its normal operations.

Next Steps and Lessons Learned

Once it is safe to resume in lab sleep studies we will
begin routine UDS for MSLT and MWT. Input from
providers, lab personal, and patients will be
considered when we determine if this intervention
is a success.

